Phaseline

Companies › Hangzhou Converd

Hangzhou Converd: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
hV01
Recombinant vaccinia virus with deletions of viral thymidine kinase (TK) and viral growth
IL21Phase 2Advanced Pancreatic Cancer; Advanced Solid TumorsJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05914376hV01Phase 1Advanced Solid TumorsOncologyJun 2027
NCT07006077hV01Phase 2Advanced Pancreatic CancerOncologyDec 2028

Targets

IL21 (1)

Companies with the same targets

–

Companies built like this

Abscint NV/SA Beijing Gene Key Life Technology CNBG-Virogin Biotech (Shanghai) Stella Pharma Dendreon

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.